Canada’s Biotechnology Sector: A Global Leader
Canada’s biotechnology industry is thriving, bolstered by increased government investment following the pandemic. This support has strengthened domestic capabilities and fostered international partnerships, enhancing drug discovery and development.
Canada has a rich history in life sciences, with significant contributions such as the development of lipid nanoparticles for mRNA vaccines by Pieter Cullis at the University of British Columbia and the discovery of stem cells at the University of Toronto. The country is also a pioneer in artificial intelligence applications in drug discovery, thanks to Nobel Laureate Geoffrey Hinton.
The biotechnology sector in Canada is home to over 1,000 companies, including global players like Roche, Novo Nordisk, AbbVie, and Amgen. Major hubs include Montreal, Toronto, and Vancouver, with Vancouver currently leading in innovation. Companies like Aspect Biosystems are pushing boundaries with bioprinted tissue therapeutics.
The federal government’s Biomanufacturing and Life Sciences Strategy, launched in 2021, aims to further strengthen the sector. This renewed focus on biotechnology is seen as essential for national security and economic growth. View the full article here.
Explore our sponsorship opportunities by featuring in our next Biopharma Dealmakers issue and become part of this dynamic and innovative sector. Partnering with us means contributing to groundbreaking advancements and supporting a thriving ecosystem. Contact us.
About Biopharma Dealmakers
Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals, and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles.
The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.
